Top Markets
#1 QuantixAI QuantixAI +32.46%
#2 Siren Siren +30.35%
#3 MowCat MowCat +27.15%
#4 Prom Prom +19.93%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +19.43%
#6 Versatize Coin Versatize Coin +16.67%
#7 Tutorial Tutorial +15.03%
#8 UnifAI Network UnifAI Network +14.50%
#9 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +14.28%
#10 Wrapped NXM Wrapped NXM +11.45%
Coin of the day
QuantixAI QuantixAI
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Sunho Biologics, Inc. Sunho Biologics, Inc.

Sunho Biologics, Inc.

2898
Rang in Aktien #20675
Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering,... Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market biological therapies. These treatments are designed to influence the body's immune system, both its inherent and adaptive responses, thereby altering the immune microenvironment. Among its portfolio is IAH0968, a monoclonal antibody specifically engineered to enhance antibody-dependent cell-mediated cytotoxicity, currently undergoing Phase II clinical trials for the treatment of biliary tract carcinoma and colorectal cancer. The company also develops IAP0971 and IAE0972, a pair of immunocytokines that have successfully concluded Phase I clinical trials for various advanced solid tumors, notably non-small cell lung cancer and colorectal cancer. Sunho Biologics also boasts a robust pipeline of early-stage assets. These include IBB0979, an immunocytokine targeting solid tumors; IBC0966, a dual-action fusion protein (anti-PD-L1 antibody-signal regulatory protein) in clinical development, designed to elicit tumor-specific immune responses; IBD0333, aimed at tumor cells; IAN0982, another oncology candidate; and immunosuppressants ISH0988 and ISH0613, which are being explored for autoimmune conditions. Established in 2018, the company operates from its headquarters in Huzhou, China, and functions as a subsidiary of Sunho Wisdom Investments Limited.
Aktienkurs
$0.81744861
Zuletzt synchronisiert: 2026-04-02
Marktkapitalisierung
$124.61M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-7.82%
Land
CN
Handel Sunho Biologics, Inc. (2898)

Kategorie

Healthcare
Gewinn für Sunho Biologics, Inc. (2898)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Sunho Biologics, Inc. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Sunho Biologics, Inc. von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH